Form 4: GeneDx Holdings CEO Sells Shares Under Pre-Arranged Trading Plan

GeneDx Holdings Corp. CEO Katherine Stueland sold 3,220 shares of Class A Common Stock for $93 per share on July 9, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp. (WGS), executed a sale of Class A Common Stock.
• The transaction involved the direct disposition of 3,220 shares of Class A Common Stock.
• The shares were sold at a price of $93 per share.
• The sale occurred on July 9, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Katherine Stueland on August 16, 2024.
• Following this sale, Katherine Stueland beneficially owns 1,720 shares of Class A Common Stock directly.
• Additionally, Katherine Stueland beneficially owns restricted stock units (RSUs) representing contingent rights to receive up to an aggregate of 473,709 shares of Class A Common Stock.
• Katherine Stueland also holds options to purchase up to an aggregate of 107,610 shares of Class A Common Stock, with both RSUs and options vesting according to their respective terms.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling by the CEO, although the impact is mitigated by the fact that it was a pre-arranged 10b5-1 plan, suggesting it was not based on new, adverse information.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, which indicates the transaction was pre-scheduled and not based on new, non-public information, enhancing transparency.

Negatives

• The sale of 3,220 shares by the Chief Executive Officer, even if planned, reduces direct ownership and could be perceived by some investors as a signal of reduced confidence or a move towards diversification/liquidity.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard insider transaction report and does not provide specific details that relate to broader industry trends or competitor activities. It reflects an individual executive's pre-planned stock sale.

Stakeholder Impact

• Shareholders may view the CEO's sale of shares with caution, potentially interpreting it as a signal, despite the 10b5-1 plan, which is designed to reduce such speculation.

Key Dates

Recommendation

Keywords

GeneDx Holdings, WGS, Insider Trading, Form 4, Stock Sale, CEO, Katherine Stueland, 10b5-1 plan, Equity Disposition